Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.

Second EUMelaReg poster at SMR congress 2023

We are proud that another EUMelaReg project was accepted for poster presentation at the SMR congress this year: “Efficacy of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment”. The development of immune checkpoint inhibitors (ICI) and targeted therapy with BRAF and MEK inhibitors, has improved the treatment of unresectable and metastatic melanoma dramatically in recent years. Postoperative treatment of patients with either anti-PD1 antibodies or BRAF and MEK inhibitors in the adjuvant setting results in better recurrence free survival rates and has therefore become the standard of care for the majority of resected stage III melanoma, particularly stage IIIB/IID. Currently, there is insufficient evidence regarding efficacy of anti-PD1 antibodies in patients who need systemic treatment after failure of adjuvant ICI. The clinical characteristics outcome of patients who underwent non adjuvant anti-PD1 treatment with pembrolizumab after failure of adjuvant anti-PD1 therapy were evaluated in 74 patients who were identified from the EUMelaReg and eligible for this analysis.